Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.
Publication
, Journal Article
Bitting, RL; Armstrong, AJ
Published in: Endocr Relat Cancer
June 2013
The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a key signaling pathway that has been linked to both tumorigenesis and resistance to therapy in prostate cancer and other solid tumors. Given the significance of the PI3K/Akt/mTOR pathway in integrating cell survival signals and the high prevalence of activating PI3K/Akt/mTOR pathway alterations in prostate cancer, inhibitors of this pathway have great potential for clinical benefit. Here, we review the role of the PI3K/Akt/mTOR pathway in prostate cancer and discuss the potential use of pathway inhibitors as single agents or in combination in the evolving treatment landscape of castration-resistant prostate cancer.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Endocr Relat Cancer
DOI
EISSN
1479-6821
Publication Date
June 2013
Volume
20
Issue
3
Start / End Page
R83 / R99
Location
England
Related Subject Headings
- TOR Serine-Threonine Kinases
- Signal Transduction
- Proto-Oncogene Proteins c-akt
- Prostatic Neoplasms, Castration-Resistant
- Phosphatidylinositol 3-Kinase
- Oncology & Carcinogenesis
- Male
- Humans
- Antineoplastic Agents
- Animals
Citation
APA
Chicago
ICMJE
MLA
NLM
Bitting, R. L., & Armstrong, A. J. (2013). Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer, 20(3), R83–R99. https://doi.org/10.1530/ERC-12-0394
Bitting, Rhonda L., and Andrew J. Armstrong. “Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.” Endocr Relat Cancer 20, no. 3 (June 2013): R83–99. https://doi.org/10.1530/ERC-12-0394.
Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer. 2013 Jun;20(3):R83–99.
Bitting, Rhonda L., and Andrew J. Armstrong. “Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.” Endocr Relat Cancer, vol. 20, no. 3, June 2013, pp. R83–99. Pubmed, doi:10.1530/ERC-12-0394.
Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer. 2013 Jun;20(3):R83–R99.
Published In
Endocr Relat Cancer
DOI
EISSN
1479-6821
Publication Date
June 2013
Volume
20
Issue
3
Start / End Page
R83 / R99
Location
England
Related Subject Headings
- TOR Serine-Threonine Kinases
- Signal Transduction
- Proto-Oncogene Proteins c-akt
- Prostatic Neoplasms, Castration-Resistant
- Phosphatidylinositol 3-Kinase
- Oncology & Carcinogenesis
- Male
- Humans
- Antineoplastic Agents
- Animals